Key points
hepatocellular damage, fibrosis
HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA, HEPATOCELLULAR DAMAGE, FIBROSIS
Lomitapide is an effective treatment for patients with homozygous familial hypercholesterolaemia which acts independently of the LDL receptor. As an inhibitor of the microsomal triglyceride transfer protein, lomitapide has been associated with a mild‐to‐moderate accumulation of hepatic fat. However, this did not translate into clinically meaningful increases in biomarkers of hepatocellular damage and hepatic imaging for fibrosis remained normal during long‐term follow‐up.